Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 9/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.38 |
| ▸ | BUB1 | O43683 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797348 | 0.78 | DRD4 (0.60) | DRD4 | |
| SCHEMBL15058458 | 0.77 | EPHA2 (0.52) | EPHA2EPHB4ERBB2DRD4SCN9A | |
| SCHEMBL8006434 | 0.76 | HTR4 (0.52) | DRD4 | |
| SCHEMBL2792532 | 0.76 | EPHA2 (0.49) | EPHA2EPHB4KDRNPC1CASP3 | |
| SCHEMBL304725 | 0.74 | KDM4E (0.51) | EPHA2EPHB4ERBB2DRD4NPC1 | |
| SCHEMBL304726 | 0.74 | KDM4E (0.51) | EPHA2EPHB4ERBB2DRD4NPC1 | |
| SCHEMBL13984639 | 0.73 | EPHA2 (0.50) | EPHA2EPHB4ERBB2DRD4BUB1 | |
| SCHEMBL1848811 | 0.73 | EPHA2 (0.50) | EPHA2EPHB4ERBB2DRD4BUB1 | |
| SCHEMBL4510923 | 0.73 | EPHA2 (0.54) | EPHA2EPHB4ERBB2DRD4RET | |
| SCHEMBL31076359 | 0.72 | EPHA2 (0.51) | EPHA2EPHB4ERBB2DRD4PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010077915-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-08 | — | — | WO | disclosed |
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-07-01 | — | — | US | disclosed |
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-07-01 | — | — | US | disclosed |
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168080-A1 | NOVEL COMPOUNDS USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR5, CCR3 | EPHA2 678/4885EPHB4 362/4885ERBB2 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.